PhD - Sam Rothstein brings more than 12 years of experience in the design of complex drug products and has led $4 million of Small Business Innovation Research grants on their development. Prior to founding Duo Oncology, Dr. Rothstein began working at the interface of cancer therapy and drug delivery as the CEO of Qrono Inc in 2017. Since joining industry in 2012, Dr. Rothstein has brought three complex drug products into IND-enabling studies.

PharmD, PhD - Katherine Eichinger is a licensed pharmacist with a master’s degree in clinical research and a doctorate in pharmaceutical science. Her experience bridges from fundamental bench research to clinical studies and includes operations experience from two major hospital systems. She has more than 10 years in preclinical research and authored eleven publications advancing science in drug pharmacology, immunology, and human disease.

PhD - Jingjing Sun has more than 10 years of experience developing nanoformulations for cancer therapy, including Duo Oncology's lead product. She is an inventor of 7 issued/pending patents in this field. She has also published one book chapter and 35 peer-reviewed papers in top journals. Dr. Sun is an Research Assistant Professor in Department of Pharmaceutical Sciences, University of Pittsburgh where she also completed a post doc.

Dr. Victoria Manax, M.D. is an accomplished medical oncologist with over two decades of expertise in the pharmaceutical/biotech industry with a focus on global drug/device development, medical affairs, and patient advocacy. Dr. Manax has played a pivotal role in the development, approval, and launch of billion-dollar products, including the standard of care nanomedicine, Abraxane, for pancreatic cancer.